{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:57:23Z","timestamp":1777712243489,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Immunopathol Pharmacol"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:p>Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve complete clearance of AKs and eliminate the risk of progression to SCC. Robust meta-analyses of trial data can provide valuable information for the optimal management of AK and cost-effectiveness evaluations of topical treatments, such as ingenol mebutate gel and diclofenac. These outcomes can facilitate prescribing physicians\u2019 decisions and shape therapeutic guidelines. Peer-reviewed meta-analysis publications and treatment guidelines favoured ingenol mebutate efficacy over diclofenac and the relative cost-effectiveness of ingenol mebutate. We discuss and critique recent evidence, from a cost-effectiveness analysis of 3% diclofenac sodium and ingenol mebutate in the treatment of AK in Italy, which has challenged this view.<\/jats:p>","DOI":"10.1177\/0394632017697719","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T03:58:22Z","timestamp":1488427102000},"page":"178-181","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacoeconomic evaluations in the treatment of actinic keratoses"],"prefix":"10.1177","volume":"30","author":[{"given":"Keith","family":"Tolley","sequence":"first","affiliation":[{"name":"Tolley Health Economics Ltd., Buxton, Derbyshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Argenziano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Second University of Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Giacomo","family":"Calzavara-Pinton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Spedali Civili di Brescia, University of Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Larsson","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S, Ballerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lasse","family":"Ryttig","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S, Ballerup, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"bibr1-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103342"},{"key":"bibr2-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.14025"},{"key":"bibr3-0394632017697719","first-page":"1727","volume":"63","author":"Braakhuis BJ","year":"2003","journal-title":"Cancer Research"},{"key":"bibr4-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.05.013"},{"key":"bibr5-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.048"},{"key":"bibr6-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00185-8"},{"key":"bibr7-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08268.x"},{"key":"bibr8-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1998.00467.x"},{"key":"bibr9-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1177\/120347540200600301"},{"key":"bibr10-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12833"},{"key":"bibr11-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.053"},{"key":"bibr12-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24284"},{"key":"bibr13-0394632017697719","first-page":"1045","volume":"32","author":"Warino L","year":"2006","journal-title":"Dermatologic Surgery"},{"key":"bibr14-0394632017697719","unstructured":"Cancer Research UK. Skin Cancer Statistics. Available at: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/skin-cancer."},{"key":"bibr15-0394632017697719","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1938"},{"key":"bibr16-0394632017697719","unstructured":"SmpC Picato\u00ae. Picato 150 mcg\/g Gel. Available at: https:\/\/www.medicines.org.uk\/emc\/medicine\/27246."},{"key":"bibr17-0394632017697719","unstructured":"SmpC Picato\u00ae. Picato 500 mcg\/g Gel. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/27247."},{"key":"bibr18-0394632017697719","unstructured":"(eMC) EMC. Solaraze SmPC. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/21229\/SPC\/Solaraze."},{"key":"bibr19-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00347.x"},{"key":"bibr20-0394632017697719","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624010-00001"},{"key":"bibr21-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"bibr22-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"bibr23-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1177\/0394632016648707"},{"key":"bibr24-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111170"},{"key":"bibr25-0394632017697719","first-page":"401","volume":"3","author":"Nelson C","year":"2004","journal-title":"Journal of Drugs in Dermatology"},{"key":"bibr26-0394632017697719","first-page":"20","volume":"2","author":"Nelson C","year":"2009","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"bibr27-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096829"},{"key":"bibr28-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-0960.2002.00635.x"},{"key":"bibr29-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2766"},{"key":"bibr30-0394632017697719","unstructured":"LEO Pharma (2015) Picato\n                      \u00ae\n                      (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information. Available at: https:\/\/www.picato.com\/_pdf\/PrescribingInformation.pdf."},{"key":"bibr31-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-015-0679-8"},{"key":"bibr32-0394632017697719","unstructured":"Werner RN, Stockfleth E, Connolly SM, (2015) Evidence and consensus based (S3) guidelines for the treatment of actinic keratosis. Available at: http:\/\/www.euroderm.org\/edf\/index.php\/edf-guidelines\/category\/5-guidelines-miscellaneous?download=23:guideline-management-of-actinic-keratoses-update-2015."},{"key":"bibr33-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0211-7"},{"key":"bibr34-0394632017697719","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2016.03.004"}],"container-title":["International Journal of Immunopathology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0394632017697719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0394632017697719","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0394632017697719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:04:42Z","timestamp":1777457082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0394632017697719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1177\/0394632017697719"],"URL":"https:\/\/doi.org\/10.1177\/0394632017697719","relation":{},"ISSN":["0394-6320","2058-7384"],"issn-type":[{"value":"0394-6320","type":"print"},{"value":"2058-7384","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}